Neogen Chemicals battery chemicals plan: FY27 target

What Neogen announced on battery chemicals

Neogen Chemicals is scaling up its battery chemicals business across electrolytes, electrolyte salts, and additives, with new capacities moving from commissioning to trial production and planned additions through FY27. The company said a 2,000 MT electrolyte plant at Dahej has been fully commissioned, marking a key operational milestone for the vertical. Alongside this, lithium electrolyte salt and additive capacities are being commissioned in phases, indicating a staggered ramp-up rather than a single-step expansion. Management has also reiterated that FY27 is expected to be a transformative year, anchored by a large battery materials plant at Pakhajan and higher utilisation at Dahej. On the financial side, the company guided for standalone FY27 revenue in the range of ₹875–950 crore. Neogen also referenced a sharp profit improvement, including a 182% jump in Q4 profit, underscoring operating leverage as capacities stabilise.

Capacity build-out at Dahej: electrolyte plant commissioned

The company said its 2,000 MT electrolyte facility at Dahej is fully commissioned. This plant is positioned as a key pillar for near-term volume growth, particularly as domestic cell manufacturing begins to scale. Neogen added that the Dahej electrolyte facility has received audit approvals from three US-based electrolyte makers, a step that typically precedes larger commercial supply relationships. Management expects the Dahej electrolyte operations to scale up during FY27, supported by improving demand visibility. Separately, Neogen referred to a Dahej replacement plant expected to be commissioned by June 2026, after which standalone operations are expected to normalise. The combination of commissioned capacity and a planned operational normalisation framework signals that FY27 is expected to be a year of both ramp-up and stabilisation.

Lithium electrolyte salts and additives: what is commissioned vs under trial

Neogen disclosed that 200 MTPA of lithium electrolyte salt and additive capacity is already commissioned. It also said 1,300 MTPA is currently under trial production, indicating the company is in the process-stabilisation phase before full commercial scaling. The company’s commentary points to a phased commissioning approach, where approvals and audits remain crucial gates for commercial supply, particularly for international customers. Neogen added that provisional approvals for electrolyte salts have been received from additional international customers, while final site audits are underway to transition to commercial supplies. In parallel, the specialised MUIS electrolyte plant has entered the trial-run phase for process stabilisation.

Next expansion leg: additions planned by Q3 FY27

Beyond commissioned and trial capacities, Neogen has outlined further additions to support growth through FY27. The company said a further 1,000 MTPA of capacity, along with 500 MT of intermediate capacity, is planned by Q3 FY27. These additions are aimed at expanding product coverage and supporting higher-value lithium salts and additives. Management’s narrative also links these expansions to a broader goal of becoming a large-scale battery materials provider rather than remaining a niche supplier. The company has also spoken about achieving full utilisation of its battery chemicals capacity by FY29, which frames the FY27 ramp-up as a mid-point in a longer investment and scale cycle.

Pakhajan greenfield project: commissioning sequence and timelines

Neogen said the Pakhajan greenfield site continues to progress in line with planned activities. Commercial manufacturing for electrolyte remains targeted for H1 FY27, while electrolyte salts are expected in H2 FY27. Management described the Pakhajan facility as one of India’s largest dedicated greenfield battery material facilities, suggesting it will be a major contributor to the battery chemicals portfolio once stabilised. In addition to these commissioning targets, the company also indicated revised scheduled commissioning dates (SCODs) under its subsidiary Neogen Ionics, with Pakhajan at June 30, 2027 and Dahej at March 31, 2027. The company’s timeline commentary also included a statement that it expects to commission both the Dahej and Pakhajan plants within FY27, reflecting a parallel track of commissioning and ramp-up.

Indo-Japan JV with Morita: LiPF6 technology and positioning

A key strategic development highlighted by the company is its Indo-Japan joint venture with Morita Investment Limited, in which Neogen holds an 80% stake. The JV is intended to use Japanese technology for producing LiPF6 salt, which is a critical component in lithium-ion battery electrolytes. Neogen positioned this as relevant for both global supply chains and India’s import substitution goals. The company’s capacity build-out and customer approval pipeline suggest it is aiming to build credibility as a qualified supplier in a highly specification-driven market. However, it has also acknowledged that customer qualification and ramp-up timelines can shift, especially when end-user cell plants delay scaling.

Demand drivers: India gigafactories and shifting local production

Neogen expects electrolyte volumes to rise as Indian battery makers accelerate local cell production after receiving government approvals. Managing Director Dr. Harin Kanani said several Indian customers had delayed ramp-ups due to pending permissions, but have now guided that they will switch their entire in-house cell consumption to local production over the next six months. He also pointed to five to six major players that are expected to start gigafactories between 2026 and 2027, including Exide, Waaree Energies, Reliance, Tata, and Amara Raja. Ola Electric’s plans to expand capacity from 5 GWh to 20 GWh were also cited as strengthening demand visibility. Neogen noted that while electrolyte salts are largely sold to international markets, electrolyte demand in India is expected to surge as local cell lines ramp.

Guidance and revisions: what the numbers say

Management guided for standalone FY27 revenue of ₹875–950 crore, and also referred to full production from MPP5 from Q2 FY26 onwards as part of the ramp-up base. Separately, Neogen revised guidance for its battery chemicals business because of delays in Indian gigafactory ramp-ups and customer approvals. It revised the revenue forecast to ₹30–40 crore from an earlier estimate of ₹300 crore, and also cited a future revenue projection of ₹400–500 crore. The company also provided a longer-term view that full utilisation of battery chemicals capacity by FY29 could support revenues of ₹2,400–2,900 crore. These figures indicate that near-term monetisation is sensitive to customer timelines, while longer-term targets depend on utilisation and qualification-driven scale-up.

Key facts table: capacity, timelines, and guidance

Market impact: what changes for investors and the battery ecosystem

The most immediate operational implication is that Neogen now has a fully commissioned 2,000 MT electrolyte plant at Dahej, which can support volume growth if domestic customers ramp cell manufacturing as indicated. Customer audits and approvals, including approvals from three US-based electrolyte makers, strengthen the company’s readiness to expand commercial supply. The staggered commissioning of lithium salts and additives, including trial production for 1,300 MTPA, suggests incremental revenue build rather than a sudden step-up. The revised battery chemicals revenue forecast to ₹30–40 crore, down from an earlier estimate of ₹300 crore, also signals that near-term performance is constrained by customer timelines rather than only by installed capacity. At the same time, the FY27 standalone revenue guidance of ₹875–950 crore frames battery chemicals as part of a broader growth and normalisation plan.

Why the developments matter: scaling, approvals, and execution risk

Neogen’s expansion highlights the execution realities of battery materials, where commissioning is only one part of scaling and customer qualification can determine when capacity converts into revenue. The company’s commentary indicates that it is building both domestic and international credibility, with audits, provisional approvals, and final site audits underway. The JV with Morita for LiPF6 technology adds another strategic layer, potentially supporting product differentiation in a market with strict performance requirements. But the revision in battery chemicals guidance due to gigafactory delays shows that demand timing can slip even when capacity is ready. For investors tracking the story, the key variables are the pace of Dahej ramp-up during FY27, progress at Pakhajan across H1 and H2 FY27 milestones, and the conversion of provisional approvals into commercial supplies.

Conclusion: what to watch through FY27

Neogen Chemicals has moved key pieces of its battery chemicals roadmap into operational and late-stage commissioning phases, led by the fully commissioned 2,000 MT electrolyte plant at Dahej. The company is also pushing lithium salt and additive capacities through commissioning and trial production, with additional capacity planned by Q3 FY27. Management has guided ₹875–950 crore standalone revenue for FY27 and has tied the year’s outlook to ramp-up at Dahej, commissioning of the Pakhajan plant, and normalisation after the Dahej replacement plant expected by June 2026. The next major checkpoints are the targeted Pakhajan electrolyte start in H1 FY27, electrolyte salts in H2 FY27, and further customer audits converting into commercial supply agreements.